Immunohistochemical expression of CD155 in invasive female breast carcinoma and its correlation with tumor infiltrating natural killer cells
Background CD155 is an immune checkpoint protein that interacts with ligands on natural killer cells to regulate the tumor associated immunity. CD155 overexpression has been detected in many human cancer types. CD155 and its pathways are promising tumor immunotherapy targets. We aimed to evaluate th...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Shibel, Passant Essam Eldin [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2023 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© The Author(s) 2023 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Beni-Suef University Journal of Basic and Applied Sciences - Bani Sweif, 2013, 12(2023), 1 vom: 13. März |
|---|---|
| Übergeordnetes Werk: |
volume:12 ; year:2023 ; number:1 ; day:13 ; month:03 |
| Links: |
|---|
| DOI / URN: |
10.1186/s43088-023-00370-z |
|---|
| Katalog-ID: |
SPR049585878 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR049585878 | ||
| 003 | DE-627 | ||
| 005 | 20230323103837.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230323s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s43088-023-00370-z |2 doi | |
| 035 | |a (DE-627)SPR049585878 | ||
| 035 | |a (SPR)s43088-023-00370-z-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shibel, Passant Essam Eldin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunohistochemical expression of CD155 in invasive female breast carcinoma and its correlation with tumor infiltrating natural killer cells |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Background CD155 is an immune checkpoint protein that interacts with ligands on natural killer cells to regulate the tumor associated immunity. CD155 overexpression has been detected in many human cancer types. CD155 and its pathways are promising tumor immunotherapy targets. We aimed to evaluate the immunohistochemical expression of CD155 in invasive breast carcinomas and to correlate such expression with the pathological parameters of the tumors and also with natural killer - tumor infiltrating lymphocytes (NK-TILs) density in breast carcinomas tissue as highlighted by CD56 immunostaining. This study included 78 cases of breast carcinomas. Immunohistochemistry was performed using antibodies against CD155 which was detected on the tumor cells and CD56 as a marker for stromal NK cells. Results CD155 expression by the tumor cells was detected in 30.8% of the cases and correlated significantly with advanced prognostic stage, Estrogen receptor (ER) and Progesterone receptor (PR) negativity, high Ki-67 index and Human epidermal receptor 2 (HER2) enriched molecular subtype. High stromal TILs CD56 expression was detected in 28.2% of the cases and correlated significantly with high histologic grade, PR negativity, HER2 neu over-expression, high Ki-67 index, high stromal TILs and more aggressive molecular subtypes; triple negative breast cancer, HER2 enriched and Luminal B-HER2 positive. Finally, statistically significant direct correlation was detected between Tumor cells CD155 expression and high TILs CD56 expression. Conclusions Our results support tumor cell CD155 expression and TILs CD56 expression in breast cancers that are high grade, TILs rich and hormone receptors negative, highlighting those cases as possible candidates for CD155 targeted therapy. | ||
| 650 | 4 | |a Breast carcinoma |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a CD155 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a CD56 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Stromal TILs |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Abd Elmaogod, Eman Ahmed |0 (orcid)0000-0001-9008-5973 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Beni-Suef University Journal of Basic and Applied Sciences |d Bani Sweif, 2013 |g 12(2023), 1 vom: 13. März |w (DE-627)784988870 |w (DE-600)2768279-1 |x 2314-8543 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:1 |g day:13 |g month:03 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s43088-023-00370-z |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a GBV_ILN_2027 | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 1 |b 13 |c 03 | ||
| author_variant |
p e e s pee pees e e a a eea eeaa |
|---|---|
| matchkey_str |
article:23148543:2023----::muoitceiaepesooc15nnaieeaeratacnmadtcreainihu |
| hierarchy_sort_str |
2023 |
| publishDate |
2023 |
| allfields |
10.1186/s43088-023-00370-z doi (DE-627)SPR049585878 (SPR)s43088-023-00370-z-e DE-627 ger DE-627 rakwb eng Shibel, Passant Essam Eldin verfasserin aut Immunohistochemical expression of CD155 in invasive female breast carcinoma and its correlation with tumor infiltrating natural killer cells 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2023 Background CD155 is an immune checkpoint protein that interacts with ligands on natural killer cells to regulate the tumor associated immunity. CD155 overexpression has been detected in many human cancer types. CD155 and its pathways are promising tumor immunotherapy targets. We aimed to evaluate the immunohistochemical expression of CD155 in invasive breast carcinomas and to correlate such expression with the pathological parameters of the tumors and also with natural killer - tumor infiltrating lymphocytes (NK-TILs) density in breast carcinomas tissue as highlighted by CD56 immunostaining. This study included 78 cases of breast carcinomas. Immunohistochemistry was performed using antibodies against CD155 which was detected on the tumor cells and CD56 as a marker for stromal NK cells. Results CD155 expression by the tumor cells was detected in 30.8% of the cases and correlated significantly with advanced prognostic stage, Estrogen receptor (ER) and Progesterone receptor (PR) negativity, high Ki-67 index and Human epidermal receptor 2 (HER2) enriched molecular subtype. High stromal TILs CD56 expression was detected in 28.2% of the cases and correlated significantly with high histologic grade, PR negativity, HER2 neu over-expression, high Ki-67 index, high stromal TILs and more aggressive molecular subtypes; triple negative breast cancer, HER2 enriched and Luminal B-HER2 positive. Finally, statistically significant direct correlation was detected between Tumor cells CD155 expression and high TILs CD56 expression. Conclusions Our results support tumor cell CD155 expression and TILs CD56 expression in breast cancers that are high grade, TILs rich and hormone receptors negative, highlighting those cases as possible candidates for CD155 targeted therapy. Breast carcinoma (dpeaa)DE-He213 CD155 (dpeaa)DE-He213 CD56 (dpeaa)DE-He213 Stromal TILs (dpeaa)DE-He213 Abd Elmaogod, Eman Ahmed (orcid)0000-0001-9008-5973 aut Enthalten in Beni-Suef University Journal of Basic and Applied Sciences Bani Sweif, 2013 12(2023), 1 vom: 13. März (DE-627)784988870 (DE-600)2768279-1 2314-8543 nnns volume:12 year:2023 number:1 day:13 month:03 https://dx.doi.org/10.1186/s43088-023-00370-z kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_2027 AR 12 2023 1 13 03 |
| spelling |
10.1186/s43088-023-00370-z doi (DE-627)SPR049585878 (SPR)s43088-023-00370-z-e DE-627 ger DE-627 rakwb eng Shibel, Passant Essam Eldin verfasserin aut Immunohistochemical expression of CD155 in invasive female breast carcinoma and its correlation with tumor infiltrating natural killer cells 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2023 Background CD155 is an immune checkpoint protein that interacts with ligands on natural killer cells to regulate the tumor associated immunity. CD155 overexpression has been detected in many human cancer types. CD155 and its pathways are promising tumor immunotherapy targets. We aimed to evaluate the immunohistochemical expression of CD155 in invasive breast carcinomas and to correlate such expression with the pathological parameters of the tumors and also with natural killer - tumor infiltrating lymphocytes (NK-TILs) density in breast carcinomas tissue as highlighted by CD56 immunostaining. This study included 78 cases of breast carcinomas. Immunohistochemistry was performed using antibodies against CD155 which was detected on the tumor cells and CD56 as a marker for stromal NK cells. Results CD155 expression by the tumor cells was detected in 30.8% of the cases and correlated significantly with advanced prognostic stage, Estrogen receptor (ER) and Progesterone receptor (PR) negativity, high Ki-67 index and Human epidermal receptor 2 (HER2) enriched molecular subtype. High stromal TILs CD56 expression was detected in 28.2% of the cases and correlated significantly with high histologic grade, PR negativity, HER2 neu over-expression, high Ki-67 index, high stromal TILs and more aggressive molecular subtypes; triple negative breast cancer, HER2 enriched and Luminal B-HER2 positive. Finally, statistically significant direct correlation was detected between Tumor cells CD155 expression and high TILs CD56 expression. Conclusions Our results support tumor cell CD155 expression and TILs CD56 expression in breast cancers that are high grade, TILs rich and hormone receptors negative, highlighting those cases as possible candidates for CD155 targeted therapy. Breast carcinoma (dpeaa)DE-He213 CD155 (dpeaa)DE-He213 CD56 (dpeaa)DE-He213 Stromal TILs (dpeaa)DE-He213 Abd Elmaogod, Eman Ahmed (orcid)0000-0001-9008-5973 aut Enthalten in Beni-Suef University Journal of Basic and Applied Sciences Bani Sweif, 2013 12(2023), 1 vom: 13. März (DE-627)784988870 (DE-600)2768279-1 2314-8543 nnns volume:12 year:2023 number:1 day:13 month:03 https://dx.doi.org/10.1186/s43088-023-00370-z kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_2027 AR 12 2023 1 13 03 |
| allfields_unstemmed |
10.1186/s43088-023-00370-z doi (DE-627)SPR049585878 (SPR)s43088-023-00370-z-e DE-627 ger DE-627 rakwb eng Shibel, Passant Essam Eldin verfasserin aut Immunohistochemical expression of CD155 in invasive female breast carcinoma and its correlation with tumor infiltrating natural killer cells 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2023 Background CD155 is an immune checkpoint protein that interacts with ligands on natural killer cells to regulate the tumor associated immunity. CD155 overexpression has been detected in many human cancer types. CD155 and its pathways are promising tumor immunotherapy targets. We aimed to evaluate the immunohistochemical expression of CD155 in invasive breast carcinomas and to correlate such expression with the pathological parameters of the tumors and also with natural killer - tumor infiltrating lymphocytes (NK-TILs) density in breast carcinomas tissue as highlighted by CD56 immunostaining. This study included 78 cases of breast carcinomas. Immunohistochemistry was performed using antibodies against CD155 which was detected on the tumor cells and CD56 as a marker for stromal NK cells. Results CD155 expression by the tumor cells was detected in 30.8% of the cases and correlated significantly with advanced prognostic stage, Estrogen receptor (ER) and Progesterone receptor (PR) negativity, high Ki-67 index and Human epidermal receptor 2 (HER2) enriched molecular subtype. High stromal TILs CD56 expression was detected in 28.2% of the cases and correlated significantly with high histologic grade, PR negativity, HER2 neu over-expression, high Ki-67 index, high stromal TILs and more aggressive molecular subtypes; triple negative breast cancer, HER2 enriched and Luminal B-HER2 positive. Finally, statistically significant direct correlation was detected between Tumor cells CD155 expression and high TILs CD56 expression. Conclusions Our results support tumor cell CD155 expression and TILs CD56 expression in breast cancers that are high grade, TILs rich and hormone receptors negative, highlighting those cases as possible candidates for CD155 targeted therapy. Breast carcinoma (dpeaa)DE-He213 CD155 (dpeaa)DE-He213 CD56 (dpeaa)DE-He213 Stromal TILs (dpeaa)DE-He213 Abd Elmaogod, Eman Ahmed (orcid)0000-0001-9008-5973 aut Enthalten in Beni-Suef University Journal of Basic and Applied Sciences Bani Sweif, 2013 12(2023), 1 vom: 13. März (DE-627)784988870 (DE-600)2768279-1 2314-8543 nnns volume:12 year:2023 number:1 day:13 month:03 https://dx.doi.org/10.1186/s43088-023-00370-z kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_2027 AR 12 2023 1 13 03 |
| allfieldsGer |
10.1186/s43088-023-00370-z doi (DE-627)SPR049585878 (SPR)s43088-023-00370-z-e DE-627 ger DE-627 rakwb eng Shibel, Passant Essam Eldin verfasserin aut Immunohistochemical expression of CD155 in invasive female breast carcinoma and its correlation with tumor infiltrating natural killer cells 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2023 Background CD155 is an immune checkpoint protein that interacts with ligands on natural killer cells to regulate the tumor associated immunity. CD155 overexpression has been detected in many human cancer types. CD155 and its pathways are promising tumor immunotherapy targets. We aimed to evaluate the immunohistochemical expression of CD155 in invasive breast carcinomas and to correlate such expression with the pathological parameters of the tumors and also with natural killer - tumor infiltrating lymphocytes (NK-TILs) density in breast carcinomas tissue as highlighted by CD56 immunostaining. This study included 78 cases of breast carcinomas. Immunohistochemistry was performed using antibodies against CD155 which was detected on the tumor cells and CD56 as a marker for stromal NK cells. Results CD155 expression by the tumor cells was detected in 30.8% of the cases and correlated significantly with advanced prognostic stage, Estrogen receptor (ER) and Progesterone receptor (PR) negativity, high Ki-67 index and Human epidermal receptor 2 (HER2) enriched molecular subtype. High stromal TILs CD56 expression was detected in 28.2% of the cases and correlated significantly with high histologic grade, PR negativity, HER2 neu over-expression, high Ki-67 index, high stromal TILs and more aggressive molecular subtypes; triple negative breast cancer, HER2 enriched and Luminal B-HER2 positive. Finally, statistically significant direct correlation was detected between Tumor cells CD155 expression and high TILs CD56 expression. Conclusions Our results support tumor cell CD155 expression and TILs CD56 expression in breast cancers that are high grade, TILs rich and hormone receptors negative, highlighting those cases as possible candidates for CD155 targeted therapy. Breast carcinoma (dpeaa)DE-He213 CD155 (dpeaa)DE-He213 CD56 (dpeaa)DE-He213 Stromal TILs (dpeaa)DE-He213 Abd Elmaogod, Eman Ahmed (orcid)0000-0001-9008-5973 aut Enthalten in Beni-Suef University Journal of Basic and Applied Sciences Bani Sweif, 2013 12(2023), 1 vom: 13. März (DE-627)784988870 (DE-600)2768279-1 2314-8543 nnns volume:12 year:2023 number:1 day:13 month:03 https://dx.doi.org/10.1186/s43088-023-00370-z kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_2027 AR 12 2023 1 13 03 |
| allfieldsSound |
10.1186/s43088-023-00370-z doi (DE-627)SPR049585878 (SPR)s43088-023-00370-z-e DE-627 ger DE-627 rakwb eng Shibel, Passant Essam Eldin verfasserin aut Immunohistochemical expression of CD155 in invasive female breast carcinoma and its correlation with tumor infiltrating natural killer cells 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2023 Background CD155 is an immune checkpoint protein that interacts with ligands on natural killer cells to regulate the tumor associated immunity. CD155 overexpression has been detected in many human cancer types. CD155 and its pathways are promising tumor immunotherapy targets. We aimed to evaluate the immunohistochemical expression of CD155 in invasive breast carcinomas and to correlate such expression with the pathological parameters of the tumors and also with natural killer - tumor infiltrating lymphocytes (NK-TILs) density in breast carcinomas tissue as highlighted by CD56 immunostaining. This study included 78 cases of breast carcinomas. Immunohistochemistry was performed using antibodies against CD155 which was detected on the tumor cells and CD56 as a marker for stromal NK cells. Results CD155 expression by the tumor cells was detected in 30.8% of the cases and correlated significantly with advanced prognostic stage, Estrogen receptor (ER) and Progesterone receptor (PR) negativity, high Ki-67 index and Human epidermal receptor 2 (HER2) enriched molecular subtype. High stromal TILs CD56 expression was detected in 28.2% of the cases and correlated significantly with high histologic grade, PR negativity, HER2 neu over-expression, high Ki-67 index, high stromal TILs and more aggressive molecular subtypes; triple negative breast cancer, HER2 enriched and Luminal B-HER2 positive. Finally, statistically significant direct correlation was detected between Tumor cells CD155 expression and high TILs CD56 expression. Conclusions Our results support tumor cell CD155 expression and TILs CD56 expression in breast cancers that are high grade, TILs rich and hormone receptors negative, highlighting those cases as possible candidates for CD155 targeted therapy. Breast carcinoma (dpeaa)DE-He213 CD155 (dpeaa)DE-He213 CD56 (dpeaa)DE-He213 Stromal TILs (dpeaa)DE-He213 Abd Elmaogod, Eman Ahmed (orcid)0000-0001-9008-5973 aut Enthalten in Beni-Suef University Journal of Basic and Applied Sciences Bani Sweif, 2013 12(2023), 1 vom: 13. März (DE-627)784988870 (DE-600)2768279-1 2314-8543 nnns volume:12 year:2023 number:1 day:13 month:03 https://dx.doi.org/10.1186/s43088-023-00370-z kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_2027 AR 12 2023 1 13 03 |
| language |
English |
| source |
Enthalten in Beni-Suef University Journal of Basic and Applied Sciences 12(2023), 1 vom: 13. März volume:12 year:2023 number:1 day:13 month:03 |
| sourceStr |
Enthalten in Beni-Suef University Journal of Basic and Applied Sciences 12(2023), 1 vom: 13. März volume:12 year:2023 number:1 day:13 month:03 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Breast carcinoma CD155 CD56 Stromal TILs |
| isfreeaccess_bool |
true |
| container_title |
Beni-Suef University Journal of Basic and Applied Sciences |
| authorswithroles_txt_mv |
Shibel, Passant Essam Eldin @@aut@@ Abd Elmaogod, Eman Ahmed @@aut@@ |
| publishDateDaySort_date |
2023-03-13T00:00:00Z |
| hierarchy_top_id |
784988870 |
| id |
SPR049585878 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">SPR049585878</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230323103837.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230323s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s43088-023-00370-z</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR049585878</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s43088-023-00370-z-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Shibel, Passant Essam Eldin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Immunohistochemical expression of CD155 in invasive female breast carcinoma and its correlation with tumor infiltrating natural killer cells</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) 2023</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background CD155 is an immune checkpoint protein that interacts with ligands on natural killer cells to regulate the tumor associated immunity. CD155 overexpression has been detected in many human cancer types. CD155 and its pathways are promising tumor immunotherapy targets. We aimed to evaluate the immunohistochemical expression of CD155 in invasive breast carcinomas and to correlate such expression with the pathological parameters of the tumors and also with natural killer - tumor infiltrating lymphocytes (NK-TILs) density in breast carcinomas tissue as highlighted by CD56 immunostaining. This study included 78 cases of breast carcinomas. Immunohistochemistry was performed using antibodies against CD155 which was detected on the tumor cells and CD56 as a marker for stromal NK cells. Results CD155 expression by the tumor cells was detected in 30.8% of the cases and correlated significantly with advanced prognostic stage, Estrogen receptor (ER) and Progesterone receptor (PR) negativity, high Ki-67 index and Human epidermal receptor 2 (HER2) enriched molecular subtype. High stromal TILs CD56 expression was detected in 28.2% of the cases and correlated significantly with high histologic grade, PR negativity, HER2 neu over-expression, high Ki-67 index, high stromal TILs and more aggressive molecular subtypes; triple negative breast cancer, HER2 enriched and Luminal B-HER2 positive. Finally, statistically significant direct correlation was detected between Tumor cells CD155 expression and high TILs CD56 expression. Conclusions Our results support tumor cell CD155 expression and TILs CD56 expression in breast cancers that are high grade, TILs rich and hormone receptors negative, highlighting those cases as possible candidates for CD155 targeted therapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Breast carcinoma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">CD155</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">CD56</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Stromal TILs</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Abd Elmaogod, Eman Ahmed</subfield><subfield code="0">(orcid)0000-0001-9008-5973</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Beni-Suef University Journal of Basic and Applied Sciences</subfield><subfield code="d">Bani Sweif, 2013</subfield><subfield code="g">12(2023), 1 vom: 13. März</subfield><subfield code="w">(DE-627)784988870</subfield><subfield code="w">(DE-600)2768279-1</subfield><subfield code="x">2314-8543</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:1</subfield><subfield code="g">day:13</subfield><subfield code="g">month:03</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/s43088-023-00370-z</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2023</subfield><subfield code="e">1</subfield><subfield code="b">13</subfield><subfield code="c">03</subfield></datafield></record></collection>
|
| author |
Shibel, Passant Essam Eldin |
| spellingShingle |
Shibel, Passant Essam Eldin misc Breast carcinoma misc CD155 misc CD56 misc Stromal TILs Immunohistochemical expression of CD155 in invasive female breast carcinoma and its correlation with tumor infiltrating natural killer cells |
| authorStr |
Shibel, Passant Essam Eldin |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)784988870 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
2314-8543 |
| topic_title |
Immunohistochemical expression of CD155 in invasive female breast carcinoma and its correlation with tumor infiltrating natural killer cells Breast carcinoma (dpeaa)DE-He213 CD155 (dpeaa)DE-He213 CD56 (dpeaa)DE-He213 Stromal TILs (dpeaa)DE-He213 |
| topic |
misc Breast carcinoma misc CD155 misc CD56 misc Stromal TILs |
| topic_unstemmed |
misc Breast carcinoma misc CD155 misc CD56 misc Stromal TILs |
| topic_browse |
misc Breast carcinoma misc CD155 misc CD56 misc Stromal TILs |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Beni-Suef University Journal of Basic and Applied Sciences |
| hierarchy_parent_id |
784988870 |
| hierarchy_top_title |
Beni-Suef University Journal of Basic and Applied Sciences |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)784988870 (DE-600)2768279-1 |
| title |
Immunohistochemical expression of CD155 in invasive female breast carcinoma and its correlation with tumor infiltrating natural killer cells |
| ctrlnum |
(DE-627)SPR049585878 (SPR)s43088-023-00370-z-e |
| title_full |
Immunohistochemical expression of CD155 in invasive female breast carcinoma and its correlation with tumor infiltrating natural killer cells |
| author_sort |
Shibel, Passant Essam Eldin |
| journal |
Beni-Suef University Journal of Basic and Applied Sciences |
| journalStr |
Beni-Suef University Journal of Basic and Applied Sciences |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2023 |
| contenttype_str_mv |
txt |
| author_browse |
Shibel, Passant Essam Eldin Abd Elmaogod, Eman Ahmed |
| container_volume |
12 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Shibel, Passant Essam Eldin |
| doi_str_mv |
10.1186/s43088-023-00370-z |
| normlink |
(ORCID)0000-0001-9008-5973 |
| normlink_prefix_str_mv |
(orcid)0000-0001-9008-5973 |
| title_sort |
immunohistochemical expression of cd155 in invasive female breast carcinoma and its correlation with tumor infiltrating natural killer cells |
| title_auth |
Immunohistochemical expression of CD155 in invasive female breast carcinoma and its correlation with tumor infiltrating natural killer cells |
| abstract |
Background CD155 is an immune checkpoint protein that interacts with ligands on natural killer cells to regulate the tumor associated immunity. CD155 overexpression has been detected in many human cancer types. CD155 and its pathways are promising tumor immunotherapy targets. We aimed to evaluate the immunohistochemical expression of CD155 in invasive breast carcinomas and to correlate such expression with the pathological parameters of the tumors and also with natural killer - tumor infiltrating lymphocytes (NK-TILs) density in breast carcinomas tissue as highlighted by CD56 immunostaining. This study included 78 cases of breast carcinomas. Immunohistochemistry was performed using antibodies against CD155 which was detected on the tumor cells and CD56 as a marker for stromal NK cells. Results CD155 expression by the tumor cells was detected in 30.8% of the cases and correlated significantly with advanced prognostic stage, Estrogen receptor (ER) and Progesterone receptor (PR) negativity, high Ki-67 index and Human epidermal receptor 2 (HER2) enriched molecular subtype. High stromal TILs CD56 expression was detected in 28.2% of the cases and correlated significantly with high histologic grade, PR negativity, HER2 neu over-expression, high Ki-67 index, high stromal TILs and more aggressive molecular subtypes; triple negative breast cancer, HER2 enriched and Luminal B-HER2 positive. Finally, statistically significant direct correlation was detected between Tumor cells CD155 expression and high TILs CD56 expression. Conclusions Our results support tumor cell CD155 expression and TILs CD56 expression in breast cancers that are high grade, TILs rich and hormone receptors negative, highlighting those cases as possible candidates for CD155 targeted therapy. © The Author(s) 2023 |
| abstractGer |
Background CD155 is an immune checkpoint protein that interacts with ligands on natural killer cells to regulate the tumor associated immunity. CD155 overexpression has been detected in many human cancer types. CD155 and its pathways are promising tumor immunotherapy targets. We aimed to evaluate the immunohistochemical expression of CD155 in invasive breast carcinomas and to correlate such expression with the pathological parameters of the tumors and also with natural killer - tumor infiltrating lymphocytes (NK-TILs) density in breast carcinomas tissue as highlighted by CD56 immunostaining. This study included 78 cases of breast carcinomas. Immunohistochemistry was performed using antibodies against CD155 which was detected on the tumor cells and CD56 as a marker for stromal NK cells. Results CD155 expression by the tumor cells was detected in 30.8% of the cases and correlated significantly with advanced prognostic stage, Estrogen receptor (ER) and Progesterone receptor (PR) negativity, high Ki-67 index and Human epidermal receptor 2 (HER2) enriched molecular subtype. High stromal TILs CD56 expression was detected in 28.2% of the cases and correlated significantly with high histologic grade, PR negativity, HER2 neu over-expression, high Ki-67 index, high stromal TILs and more aggressive molecular subtypes; triple negative breast cancer, HER2 enriched and Luminal B-HER2 positive. Finally, statistically significant direct correlation was detected between Tumor cells CD155 expression and high TILs CD56 expression. Conclusions Our results support tumor cell CD155 expression and TILs CD56 expression in breast cancers that are high grade, TILs rich and hormone receptors negative, highlighting those cases as possible candidates for CD155 targeted therapy. © The Author(s) 2023 |
| abstract_unstemmed |
Background CD155 is an immune checkpoint protein that interacts with ligands on natural killer cells to regulate the tumor associated immunity. CD155 overexpression has been detected in many human cancer types. CD155 and its pathways are promising tumor immunotherapy targets. We aimed to evaluate the immunohistochemical expression of CD155 in invasive breast carcinomas and to correlate such expression with the pathological parameters of the tumors and also with natural killer - tumor infiltrating lymphocytes (NK-TILs) density in breast carcinomas tissue as highlighted by CD56 immunostaining. This study included 78 cases of breast carcinomas. Immunohistochemistry was performed using antibodies against CD155 which was detected on the tumor cells and CD56 as a marker for stromal NK cells. Results CD155 expression by the tumor cells was detected in 30.8% of the cases and correlated significantly with advanced prognostic stage, Estrogen receptor (ER) and Progesterone receptor (PR) negativity, high Ki-67 index and Human epidermal receptor 2 (HER2) enriched molecular subtype. High stromal TILs CD56 expression was detected in 28.2% of the cases and correlated significantly with high histologic grade, PR negativity, HER2 neu over-expression, high Ki-67 index, high stromal TILs and more aggressive molecular subtypes; triple negative breast cancer, HER2 enriched and Luminal B-HER2 positive. Finally, statistically significant direct correlation was detected between Tumor cells CD155 expression and high TILs CD56 expression. Conclusions Our results support tumor cell CD155 expression and TILs CD56 expression in breast cancers that are high grade, TILs rich and hormone receptors negative, highlighting those cases as possible candidates for CD155 targeted therapy. © The Author(s) 2023 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_2027 |
| container_issue |
1 |
| title_short |
Immunohistochemical expression of CD155 in invasive female breast carcinoma and its correlation with tumor infiltrating natural killer cells |
| url |
https://dx.doi.org/10.1186/s43088-023-00370-z |
| remote_bool |
true |
| author2 |
Abd Elmaogod, Eman Ahmed |
| author2Str |
Abd Elmaogod, Eman Ahmed |
| ppnlink |
784988870 |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.1186/s43088-023-00370-z |
| up_date |
2024-07-04T01:25:53.785Z |
| _version_ |
1803609811241140224 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">SPR049585878</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230323103837.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230323s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s43088-023-00370-z</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR049585878</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s43088-023-00370-z-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Shibel, Passant Essam Eldin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Immunohistochemical expression of CD155 in invasive female breast carcinoma and its correlation with tumor infiltrating natural killer cells</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) 2023</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background CD155 is an immune checkpoint protein that interacts with ligands on natural killer cells to regulate the tumor associated immunity. CD155 overexpression has been detected in many human cancer types. CD155 and its pathways are promising tumor immunotherapy targets. We aimed to evaluate the immunohistochemical expression of CD155 in invasive breast carcinomas and to correlate such expression with the pathological parameters of the tumors and also with natural killer - tumor infiltrating lymphocytes (NK-TILs) density in breast carcinomas tissue as highlighted by CD56 immunostaining. This study included 78 cases of breast carcinomas. Immunohistochemistry was performed using antibodies against CD155 which was detected on the tumor cells and CD56 as a marker for stromal NK cells. Results CD155 expression by the tumor cells was detected in 30.8% of the cases and correlated significantly with advanced prognostic stage, Estrogen receptor (ER) and Progesterone receptor (PR) negativity, high Ki-67 index and Human epidermal receptor 2 (HER2) enriched molecular subtype. High stromal TILs CD56 expression was detected in 28.2% of the cases and correlated significantly with high histologic grade, PR negativity, HER2 neu over-expression, high Ki-67 index, high stromal TILs and more aggressive molecular subtypes; triple negative breast cancer, HER2 enriched and Luminal B-HER2 positive. Finally, statistically significant direct correlation was detected between Tumor cells CD155 expression and high TILs CD56 expression. Conclusions Our results support tumor cell CD155 expression and TILs CD56 expression in breast cancers that are high grade, TILs rich and hormone receptors negative, highlighting those cases as possible candidates for CD155 targeted therapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Breast carcinoma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">CD155</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">CD56</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Stromal TILs</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Abd Elmaogod, Eman Ahmed</subfield><subfield code="0">(orcid)0000-0001-9008-5973</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Beni-Suef University Journal of Basic and Applied Sciences</subfield><subfield code="d">Bani Sweif, 2013</subfield><subfield code="g">12(2023), 1 vom: 13. März</subfield><subfield code="w">(DE-627)784988870</subfield><subfield code="w">(DE-600)2768279-1</subfield><subfield code="x">2314-8543</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:1</subfield><subfield code="g">day:13</subfield><subfield code="g">month:03</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/s43088-023-00370-z</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2023</subfield><subfield code="e">1</subfield><subfield code="b">13</subfield><subfield code="c">03</subfield></datafield></record></collection>
|
| score |
7.402231 |